Fourteen Abstracts Featuring MedImmune's Influenza and RSV Therapeutic Areas to Be Presented at Pediatric Academic Societies Annual Meeting
"Our rich history in pediatric research is a pillar of our strength atMedImmune and we believe the collective data we share at PAS will help furtherthe understanding of prevention around two important infectious diseases thatimpact the health of children," said Alexander A. Zukiwski, M.D., senior vicepresident and chief medical officer. "Ongoing research from our portfolio ofcurrent and emerging biologics reflects our commitment to finding importantnew solutions for pediatric infectious disease prevention."
Immunogenicity of Live Attenuated Influenza Vaccine (LAIV) Compared WithTrivalent Inactivated Influenza Vaccine (TIV) in Children 12-35 Months ofAge(1) (Harvey BM, et al)
(1) Do not administer FluMist to children less than two years of age dueto an increased risk of hospitalization and wheezing that was observed inclinical trials.
Shedding and Safety of Live Attenuated Influenza Vaccine in HealthySubjects 6 to <60 Months of Age(1) (Block SL, Reisinger KS)
Efficacy, Immunogenicity, and Safety of One Versus Two Doses of LAIV inYoung Children (Bracco H, et al)
Cost-Effectiveness of Live Attenuated Influenza Vaccine Versus InactivatedInfluenza Vaccine Among Children Aged 24 to 59 Months (Luce B, et al)
Real-Time Assessment of 2007-2008 Influenza Vaccine Coverage AmongPracticing Pediatricians (Bhatt P, et al)
Efficacy of Live Attenuated Influenza Vaccine in Children: A Meta-Analysisof 9 Randomized Clinical Trials (Rhorer J, et al)
Early Availability of Influenza Vaccine Could Double In-Office VaccinationOpportunities (Ambrose CS, et al)
Genetic Sequences of Circulating 2004-2005 Influenza Strains and SerumAntibody Responses to LAIV vs. TIV in Young Children (Belshe RB, et al)
A total of five studies related to MedImmune's respiratory syncytial virus(RSV) marketed and investigational products are scheduled for presentation atthe PAS meeting. Among these are two studies related to epidemiology andpharmacoeconomics of RSV, and one each related to Synagis(R) (palivizumab),motavizumab and MEDI-534. Results of these studies are scheduled to bepresented as follows:
Seasonality of Respiratory Syncytial Virus-Associated Lower RespiratoryTract Infection (LRI) and Apnea in Infants Presenting to the EmergencyDepartment (ED) (Bonner A, et al)
Phase 1 study of MEDI-534, a Live Attenuated Vaccine Candidate AgainstRespiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) inHealthy 1-9 Year-Old RSV and PIV3 Seropositive Children (Gomez M, et al)
Lung Function in Healthy Late Preterm Infants Delivered at 33-36 Weeks ofGestation (Venigalla S, et al)
Safety and Efficacy of motavizumab in the Prevention of RSV Disease inHealthy Infants (Chandran A, et al)
FluMist(R) (Influenza Virus Vaccine Live, Intranasal) is a live attenuatedinfluenza virus vaccine indicated for active immunization of individuals twoto 49 years of age against influenza disease caused by influenza virussubtypes A and type B contained in the vaccine.
FluMist is contraindicated in individuals with history of hypersensitivityto eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children andadolescents receiving concomitant aspirin or aspirin-containing therapy.
Do not administer FluMist to children less than two years of age due to an
You May Also Like